Pharma companies set for strong performance in March 2025 quarter amid earning (...)
Sun Pharma is expected to post a 9% year-on-year revenue growth, supported by its US specialty portfolio and steady growth in chronic therapies in India.
Site référencé: The Economic Times
The Economic Times
From tariff cuts to MSP rollback : GTRI on likely US demands in India trade deal
4/05/2025
8 Nifty Microcap stocks that can jump 100-230% in the next 12 months
4/05/2025
At all-time highs, is gold overpriced ? Not according to Sunil Subramaniam
4/05/2025
UK police arrest five men, including four Iranians, over suspected terror plot
4/05/2025
Trump brands his opponents as 'communists,' label loaded with baggage of American history
3/05/2025
Buffett says US shouldn't use "trade as a weapon" as Trump has done with tariffs
3/05/2025
